IGC Pharma, Inc. (formerly India Globalization Capital, Inc.) Overview
Pro stress-test →IGC Pharma, Inc., a clinical stage pharmaceutical company, develops treatments for Alzheimer's disease in the United States and Colombia. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company has undergone significant strategic transformation from its original infrastructure commodities business to focus on innovative neurodegenerative disease therapeutics.
Strategic Profile
Pro stress-test →The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's, with pre-clinical stage product candidates including TGR-63, IGC-M3, and LMP to treat Alzheimer's disease. As a micro-cap biotech player, IGC Pharma is pursuing high-risk, high-reward clinical development in a large therapeutic market with significant unmet medical needs in Alzheimer's treatment.
Competitive Landscape
Pro stress-test →IGC Pharma competes in the crowded Alzheimer's therapeutics market against larger pharmaceutical companies and other biotech firms with greater resources. Competitors include companies developing cognitive decline treatments, agitation management therapies, and novel disease-modifying approaches. The company's micro-cap status and limited funding create competitive disadvantages versus well-capitalized rivals.
Industry Context
IGC Pharma, Inc. (formerly India Globalization Capital, Inc.) operates in Biopharmaceutical / Clinical Stage Pharmaceutical Development.
Key facts
Founded: 2005 · Headquarters: Potomac, Maryland · Market cap: $26.04M